文献速递细菌感染、耐药与抗菌药物医院感染防控

金黄色葡萄球菌菌血症患者血源性椎体骨髓炎的危险因素与结局

Risk Factors and Outcomes of Hematogenous Vertebral Osteomyelitis in Patients With Staphylococcus aureus Bacteremia.
PubMed 文献 · Clin Infect Dis · 2023-01-01

研究前瞻性纳入1995至2019年杜克大学健康系统3165例金黄色葡萄球菌菌血症患者,其中127例(4.0%)发生血源性椎体骨髓炎。HVOM风险与社区获得性菌血症、诊断时间较长和持续性菌血症相关,而与细菌基因型无关;HVOM患者12个月随访全因死亡率达22%。

要点

  • 3165例金黄色葡萄球菌菌血症中127例(4.0%)发生血源性椎体骨髓炎。
  • HVOM患者更常见社区获得性菌血症(30.7% vs 16.7%,P < .001)和持续性菌血症(48.8% vs 20.6%,P < .001)。
  • HVOM患者12个月随访全因死亡率为22%,存活者中29.6%出现HVOM或菌血症复发。

核心结论

  • 在金黄色葡萄球菌菌血症患者中,HVOM风险与临床因素相关,而与细菌基因型无关。
  • 尽管HVOM是菌血症的罕见并发症,但HVOM患者诊断后1年内全因死亡率和医疗资源需求均较高。
  • 作者认为应对这一脆弱人群进行密切临床监测。

研究设计与样本

  • 前瞻性纳入1995年至2019年杜克大学健康系统的合格金黄色葡萄球菌菌血症患者,比较有无HVOM者。
  • HVOM通过影像学或微生物学诊断。
  • 采用多变量logistic回归分析识别与HVOM风险相关的临床和微生物因素。
  • 所有血流金黄色葡萄球菌分离株均采用spa分型进行基因分型。

主要发现

  • 3165例金黄色葡萄球菌菌血症中127例(4.0%)发生HVOM。
  • HVOM患者社区获得性菌血症比例为30.7% vs 16.7%(P < .001)。
  • HVOM患者诊断菌血症时间中位数5天(IQR 2-10.5)vs 2天(IQR 0-4)(P < .001)。
  • HVOM患者持续性菌血症比例为48.8% vs 20.6%(P < .001)。
  • HVOM患者感染性心内膜炎发生率为26% vs 15.2%(P = .002)。

关键数值与推荐

  • HVOM患者中26.2%(n = 33)接受外科干预。
  • 甲氧西林耐药比例46.6% vs 41.7%(P = .318),与HVOM发生无关。
  • 细菌基因型与HVOM发生无关。
  • 12个月随访时,22%的HVOM患者死亡。
  • 存活患者中20.4%仍接受抗生素治疗,29.6%出现HVOM或菌血症复发。

临床怎么用

  • 作者认为应对金黄色葡萄球菌菌血症后发生HVOM的这一脆弱人群进行密切临床监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hematogenous vertebral osteomyelitis (HVOM) is an incompletely understood complication of Staphylococcus aureus bacteremia (SAB). METHODS: Eligible SAB patients with and without HVOM were prospectively enrolled from 1995 through 2019 at Duke University Health System. HVOM was diagnosed either radiographically or microbiologically. Multivariable logistic regression analysis was performed to identify clinical and microbial factors associated with HVOM risk. All bloodstream S. aureus isolates were genotyped using spa typing. RESULTS: Of 3165 cases of SAB, 127 (4.0%) developed HVOM. Patients who experienced HVOM were more likely to have community-acquired SAB (30.7% vs 16.7%, P < .001), have a longer time to diagnosis of SAB (median, 5 days; interquartile range [IQR], 2-10.5 vs median, 2 days; IQR, 0-4; P < .001), and to exhibit persistent bacteremia (48.8% vs 20.6%, P < .001). A significant number of HVOM patients developed infective endocarditis (26% vs 15.2%, P = .002). Overall, 26.2% (n = 33) of SAB patients with HVOM underwent surgical intervention. Methicillin resistance (46.6% vs 41.7%, P = .318) and bacterial genotype were not associated with the development of HVOM. At the 12-month follow-up, 22% of patients with HVOM had died. Of the surviving patients, 20.4% remained on antibiotic therapy, and 29.6% had recurrence of either HVOM or SAB. CONCLUSIONS: Among patients with SAB, HVOM risk was associated with clinical factors and not bacterial genotype. Despite being a rare complication of SAB, patients with HVOM had high all-cause mortality rates and healthcare resource requirements up to 1 year after their HVOM diagnosis. Close clinical monitoring is indicated in this vulnerable population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kinamon T, Dagher M, Park L, et al. Risk Factors and Outcomes of Hematogenous Vertebral Osteomyelitis in Patients With Staphylococcus aureus Bacteremia. Clin Infect Dis. 2023. PMID: 37747828. doi:10.1093/cid/ciad377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。